Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion type Assertion NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_head.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion wasGeneratedBy ECO_0000203 NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_provenance.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion wasDerivedFrom befree-20140225 NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_provenance.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion SIO_000772 22421340 NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_provenance.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion evidence source_evidence_literature NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_provenance.
- NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_assertion description "[This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456252.RAxGbztUg04Jf60_FFM5Fk-ydSlyWcDVwsHU8kXeRVR5w130_provenance.